How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
"With Clarient's ACIS platform, Carl Zeiss MicroImaging acquires the gold standard for tissue based cancer diagnostics. This acquisition will complement Zeiss' strong portfolio of micro-imaging technologies," commented Ulrich Simon, President and CEO of Germany-based Carl Zeiss MicroImaging GmbH, and responsible for the global Microscopy business of Carl Zeiss . "The acquisition demonstrates once again that Carl Zeiss MicroImaging actively invests into innovative technologies. We are delighted that the agreement also contains arrangements for establishing a continued co-operation with Clarient's innovative Lab Service Business in the field of rare event detection."
Susquehanna Financial Group, LLLP, an affiliate of Susquehanna International Group, LLP, acted as exclusive financial advisor to Clarient inconnection with the transaction.
Clarient will discuss the sale of its instrument business and the Zeiss partnership on a conference call and live webcast at 4:30 PM ET today. Dial-in participants can call 888-666-8774 or 706-679-7717 for international callers.Please reference the Clarient conference call. The webcast can be accessed by visiting http://www.clarientinc.com/investor.
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The Company was formed in 1996 to develop and market the ACIS(R) Automated Cellular Imaging System, an important advance in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide the full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing the most advanced oncology testing and drug development services available. Clarient is a Safeguard Scientifics, Inc. partner company. Formore information, visit www.clarientinc.com.